EX-99.1 2 d416189dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

 

LOGO

 

For investors    For media
Amy Wakeham    Jayme Rubenstein
+1 858-836-5000    +1 858-836-6798
investorrelations@resmed.com    news@resmed.com

ResMed Inc. Announces Results for the First Quarter of Fiscal Year 2023

Year-over-year revenue grows 5%, operating profit up 5%, non-GAAP operating profit up 4%

Note: A webcast of ResMed’s conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com

SAN DIEGO, October 27, 2022 – ResMed Inc. (NYSE: RMD, ASX: RMD) today announced results for its quarter ended September 30, 2022.

First Quarter 2023 Highlights

All comparisons are to the prior year period

 

   

Revenue increased by 5% to $950.3 million; up 9% on a constant currency basis

 

   

Gross margin expanded by 90 bps to 56.9%; non-GAAP gross margin expanded by 40 bps to 57.6%

 

   

Income from operations increased 5%; non-GAAP operating profit up 4%

 

   

Diluted earnings per share of $1.43; non-GAAP diluted earnings per share of $1.51

“Our first quarter fiscal year 2023 results demonstrate strong sales growth in the Americas and solid overall performance for our businesses,” said Mick Farrell, ResMed’s CEO. “Our global ResMed team continues to power through the dynamic supply chain environment to increase production volumes and deliver more products and software solutions into the hands of people who need them. During the quarter we saw strong customer uptake of our reengineered AirSense 10 Card-to-Cloud device. We also continued to increase our access to semiconductor communications chips, allowing us to produce more of our industry-leading, 100%-connectable platforms. Looking ahead, we remain focused on delivering life-saving therapy solutions and driving accelerated adoption of digital health in sleep apnea, respiratory care, and out-of-hospital care. I am confident in our growth strategy and our ability to accelerate toward our goal of improving 250 million lives in 2025.”


 

RMD First Quarter 2023 Earnings Press Release October 27, 2022   Page of 10

 

Financial Results and Operating Metrics

Unaudited; $ in millions, except for per share amounts

 

     Three Months Ended  
     September 30,
2022
    September 30,
2021
    % Change     Constant
Currency (A)
 

Revenue

   $ 950.3     $ 904.0       5     9

Gross margin

     56.9     56.0     2    

Non-GAAP gross margin (B)

     57.6     57.2     1    

Selling, general, and administrative expenses

     193.9       176.7       10       16  

Research and development expenses

     63.2       60.0       5       9  

Income from operations

     275.7       261.9       5    

Non-GAAP income from operations (B)

     290.8       280.7       4    

Net income

     210.5       203.6       3    

Non-GAAP net income (B)

     222.1       222.0       Nil    

Diluted earnings per share

   $ 1.43     $ 1.39       3    

Non-GAAP diluted earnings per share (B)

   $ 1.51     $ 1.51       Nil    

 

(A)

In order to provide a framework for assessing how our underlying businesses performed excluding the effect of foreign currency fluctuations, we provide certain financial information on a “constant currency” basis, which is in addition to the actual financial information presented. In order to calculate our constant currency information, we translate the current period financial information using the foreign currency exchange rates that were in effect during the previous comparable period. However, constant currency measures should not be considered in isolation or as an alternative to U.S. dollar measures that reflect current period exchange rates, or to other financial measures calculated and presented in accordance with U.S. GAAP.

(B)

See the reconciliation of non-GAAP financial measures in the table at the end of the press release.

Discussion of First Quarter Results

All comparisons are to the prior year period unless otherwise noted

 

 

Revenue grew by 9 percent on a constant currency basis, driven by increased demand for our sleep and respiratory care devices as well as reduced competitive supply.

 

   

Revenue in the U.S., Canada, and Latin America, excluding Software-as-a-Service, grew by 18 percent, primarily due to the factors discussed above and recovery of core sleep patient flow that was previously impacted by COVID-19.

 

   

Revenue in Europe, Asia, and other markets declined by 6 percent on a constant currency basis.

 

   

Software-as-a-Service revenue increased by 9 percent, due to continued growth in our Home Medical Equipment vertical.

 

 

Gross margin increased by 90 basis points and non-GAAP gross margin increased by 40 basis points, mainly due to an increase in average selling prices, partially offset by unfavorable product mix and foreign currency movements.

 

 

Selling, general, and administrative expenses increased by 16 percent on a constant currency basis. SG&A expenses increased to 20.4 percent of revenue in the quarter, compared with 19.5 percent in the same period of the prior year. These changes in SG&A expenses were mainly due to increases in employee-related expenses and increases in travel expenses.

 

 

Income from operations increased by 5 percent and non-GAAP income from operations increased by 4 percent.


 

RMD First Quarter 2023 Earnings Press Release October 27, 2022   Page of 10

 

 

Net income for the quarter was $210.5 million and diluted earnings per share was $1.43. Non-GAAP net income was $222.1 million, and non-GAAP diluted earnings per share was $1.51, both consistent with the same period of the prior year.

 

 

Operating cash flow for the quarter was $44.7 million, reflecting the impact of increases in working capital. During the quarter we paid $64.4 million in dividends.

Other Business and Operational Highlights

 

 

Announced the acquisition of mementor, a German pioneer and health tech startup that develops and distributes digital medical products in the field of sleep medicine and related areas. mementor offers the first permanently approved Digital Health Application (DiGA), somnio, eligible for reimbursement in the field of sleep medicine.

 

 

Celebrated the official opening of ResMed’s new technology R&D facility in Ireland (Sandyford in Dublin) and announced a plan to double the Ireland-based software and technology team with 70 jobs over the next four years to support innovation, technology development, and product development.

 

 

Released updated global chronic obstructive pulmonary disease (COPD) prevalence numbers via a late-breaking abstract at the European Respiratory Society Congress. Based on ResMed’s updated research, it’s estimated over 480 million people worldwide suffer from COPD, a 22-126% increase over today’s most cited resources.

Dividend program

The ResMed board of directors today declared a quarterly cash dividend of $0.44 per share. The dividend will have a record date of November 10, 2022, payable on December 15, 2022. The dividend will be paid in U.S. currency to holders of ResMed’s common stock trading on the New York Stock Exchange. Holders of CHESS Depositary Interests (“CDIs”) trading on the Australian Securities Exchange will receive an equivalent amount in Australian currency, based on the exchange rate on the record date, and reflecting the 10:1 ratio between CDIs and NYSE shares. The ex-dividend date will be November 9, 2022, for common stockholders and for CDI holders. ResMed has received a waiver from the ASX’s settlement operating rules, which will allow ResMed to defer processing conversions between its common stock and CDI registers from November 9, 2022, through November 10, 2022, inclusive.

Webcast details

ResMed will discuss its first-quarter fiscal year 2023 results on its webcast at 1:30 p.m. U.S. Pacific Time today. The live webcast of the call can be accessed on ResMed’s Investor Relations website at investor.resmed.com. Please go to this section of the website and click on the icon for the “Q1 2023 Earnings Webcast” to register and listen to the live webcast. A replay of the earnings webcast will be accessible on the website and available approximately two hours after the live webcast. In addition, a telephone replay of the conference call will be available approximately two hours after the webcast by dialing +1 877-660-6853 (U.S.) or +1 201-612-7415 (outside U.S.) and entering the passcode 13733726. The telephone replay will be available until November 10, 2022.


 

RMD First Quarter 2023 Earnings Press Release October 27, 2022   Page of 10

 

About ResMed

At ResMed (NYSE: RMD, ASX: RMD) we pioneer innovative solutions that treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives. Our digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, COPD, and other chronic diseases. Our comprehensive out-of-hospital software platforms support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. By enabling better care, we improve quality of life, reduce the impact of chronic disease, and lower costs for consumers and healthcare systems in more than 140 countries. To learn more, visit ResMed.com and follow @ResMed.

Safe harbor statement

Statements contained in this release that are not historical facts are “forward-looking” statements as contemplated by the Private Securities Litigation Reform Act of 1995. These forward-looking statements – including statements regarding ResMed’s projections of future revenue or earnings, expenses, new product development, new product launches, new markets for its products, the integration of acquisitions, litigation, and tax outlook – are subject to risks and uncertainties, which could cause actual results to materially differ from those projected or implied in the forward-looking statements. Additional risks and uncertainties are discussed in ResMed’s periodic reports on file with the U.S. Securities & Exchange Commission. ResMed does not undertake to update its forward-looking statements.

– More –


 

RMD First Quarter 2023 Earnings Press Release October 27, 2022   Page of 10

 

RESMED INC. AND SUBSIDIARIES

 

Condensed Consolidated Statements of Operations

(Unaudited; $ in thousands, except for per share amounts)

 

     Three Months Ended  
     September 30,
2022
    September 30,
2021
 

Net revenue

   $ 950,294     $ 904,015  

Cost of sales

     403,110       386,667  

Amortization of acquired intangibles (1)

     6,374       11,059  
  

 

 

   

 

 

 

Total cost of sales

   $ 409,484     $ 397,726  
  

 

 

   

 

 

 

Gross profit

   $ 540,810     $ 506,289  

Selling, general, and administrative

     193,933       176,719  

Research and development

     63,188       59,950  

Amortization of acquired intangibles (1)

     7,950       7,707  

Total operating expenses

   $ 265,071     $ 244,376  

Income from operations

     275,739       261,913  

Other income (expenses), net:

    

Interest income (expense), net

   $ (7,134   $ (5,360

Loss attributable to equity method investments

     (2,028     (1,386

Gain (loss) on equity investments

     (3,280     5,612  

Other, net

     (1,504     (1,991
  

 

 

   

 

 

 

Total other income (expenses), net

     (13,946     (3,125
  

 

 

   

 

 

 

Income before income taxes

   $ 261,793     $ 258,788  

Income taxes

     51,315       55,175  
  

 

 

   

 

 

 

Net income

   $ 210,478     $ 203,613  
  

 

 

   

 

 

 

Basic earnings per share

   $ 1.44     $ 1.40  

Diluted earnings per share

   $ 1.43     $ 1.39  

Non-GAAP diluted earnings per share (1)

   $ 1.51     $ 1.51  

Basic shares outstanding

     146,431       145,680  

Diluted shares outstanding

     147,134       146,860  

 

(1)

See the reconciliation of non-GAAP financial measures in the table at the end of the press release.

– More –


 

RMD First Quarter 2023 Earnings Press Release – October 27, 2022   Page of 10

 

RESMED INC. AND SUBSIDIARIES

 

Condensed Consolidated Balance Sheets

(Unaudited; $ in thousands)

 

     September 30,
2022
    June 30,
2022
 

ASSETS

    

Current assets:

    

Cash and cash equivalents

   $ 207,163     $ 273,710  

Accounts receivable, net

     620,483       575,950  

Inventories

     864,852       743,910  

Prepayments and other current assets

     341,199       337,908  
  

 

 

   

 

 

 

Total current assets

   $ 2,033,697     $ 1,931,478  

Non-current assets:

    

Property, plant, and equipment, net

   $ 487,376     $ 498,181  

Operating lease right-of-use assets

     125,319       132,314  

Goodwill and other intangibles, net

     2,276,994       2,282,386  

Deferred income taxes and other non-current assets

     254,174       251,494  
  

 

 

   

 

 

 

Total non-current assets

   $ 3,143,863     $ 3,164,375  
  

 

 

   

 

 

 

Total assets

   $ 5,177,560     $ 5,095,853  
  

 

 

   

 

 

 

LIABILITIES AND STOCKHOLDERS’ EQUITY:

    

Current liabilities:

    

Accounts payable

   $ 181,485     $ 159,245  

Accrued expenses

     324,055       344,722  

Operating lease liabilities, current

     21,076       21,856  

Deferred revenue

     108,195       108,667  

Income taxes payable

     47,942       44,893  

Short-term debt

     9,906       9,916  
  

 

 

   

 

 

 

Total current liabilities

   $ 692,659     $ 689,299  

Non-current liabilities:

    

Deferred revenue

   $ 97,620     $ 95,455  

Deferred income taxes

     11,830       9,714  

Operating lease liabilities, non-current

     114,214       120,453  

Other long-term liabilities

     5,838       5,974  

Long-term debt

     785,436       765,325  

Long-term income taxes payable

     37,076       48,882  
  

 

 

   

 

 

 

Total non-current liabilities

   $ 1,052,014     $ 1,045,803  
  

 

 

   

 

 

 

Total liabilities

   $ 1,744,673     $ 1,735,102  
  

 

 

   

 

 

 

STOCKHOLDERS’ EQUITY:

    

Common stock

   $ 586     $ 586  

Additional paid-in capital

     1,701,902       1,682,432  

Retained earnings

     3,759,783       3,613,736  

Treasury stock

     (1,623,256     (1,623,256

Accumulated other comprehensive income

     (406,128     (312,747
  

 

 

   

 

 

 

Total stockholders’ equity

   $ 3,432,887     $ 3,360,751  
  

 

 

   

 

 

 

Total liabilities and stockholders’ equity

   $ 5,177,560     $ 5,095,853  
  

 

 

   

 

 

 

– More –


 

RMD First Quarter 2023 Earnings Press Release – October 27, 2022   Page 7 of 10

 

RESMED INC. AND SUBSIDIARIES

 

Condensed Consolidated Statements of Cash Flows

(Unaudited; $ in thousands)

 

     Three months ended  
     September 30,
2022
    September 30,
2021
 

Cash flows from operating activities:

    

Net income

   $ 210,478     $ 203,613  

Adjustment to reconcile net income to cash provided by operating activities:

    

Depreciation and amortization

     36,273       39,102  

Amortization of right-of-use assets

     7,761       8,517  

Stock-based compensation costs

     16,919       17,303  

Loss attributable to equity method investments

     2,028       1,386  

(Gain) loss on equity investment

     3,280       (5,612

Changes in operating assets and liabilities:

    

Accounts receivable, net

     (56,238     33,704  

Inventories, net

     (147,096     (55,976

Prepaid expenses, net deferred income taxes and other current assets

     (36,784     (14,391

Accounts payable, accrued expenses, income taxes payable and other

     8,041       (293,303
  

 

 

   

 

 

 

Net cash (used in) / provided by operating activities

   $ 44,662     $ (65,657

Cash flows from investing activities:

    

Purchases of property, plant, and equipment

     (29,056     (27,340

Patent registration and acquisition costs

     (3,317     (4,453

Business acquisitions, net of cash acquired

     (19,100     —    

Purchases of investments

     (4,291     (6,600

(Payments) / proceeds on maturity of foreign currency contracts

     (3,042     (3,481
  

 

 

   

 

 

 

Net cash used in investing activities

   $ (58,806   $ (41,874

Cash flows from financing activities:

    

Proceeds from issuance of common stock, net

     2,610       4,354  

Taxes paid related to net share settlement of equity awards

     (59     (195

Proceeds from borrowings, net of borrowing costs

     50,000       150,000  

Repayment of borrowings

     (30,000     —    

Dividends paid

     (64,431     (61,189
  

 

 

   

 

 

 

Net cash (used in) / provided by financing activities

   $ (41,880   $ 92,970  
  

 

 

   

 

 

 

Effect of exchange rate changes on cash

   $ (10,523   $ (4,568
  

 

 

   

 

 

 

Net increase / (decrease) in cash and cash equivalents

     (66,547     (19,129

Cash and cash equivalents at beginning of period

     273,710       295,278  
  

 

 

   

 

 

 

Cash and cash equivalents at end of period

   $ 207,163     $ 276,149  
  

 

 

   

 

 

 

– More –


 

RMD First Quarter 2023 Earnings Press Release October 27, 2022   Page of 10

 

RESMED INC. AND SUBSIDIARIES

 

Reconciliation of Non-GAAP Financial Measures

(Unaudited; $ in thousands, except for per share amounts)

The measures “non-GAAP gross profit” and “non-GAAP gross margin” exclude amortization expense from acquired intangibles related to cost of sales and are reconciled below:

 

     Three Months Ended  
     September 30,
2022
    September 30,
2021
 

Revenue

   $ 950,294     $ 904,015  

GAAP cost of sales

   $ 409,484     $ 397,726  

Less: Amortization of acquired intangibles (A)

     (6,374     (11,059
  

 

 

   

 

 

 

Non-GAAP cost of sales

   $ 403,110     $ 386,667  

GAAP gross profit

   $ 540,810     $ 506,289  

GAAP gross margin

     56.9     56.0

Non-GAAP gross profit

   $ 547,184     $ 517,348  

Non-GAAP gross margin

     57.6     57.2

The measure “non-GAAP income from operations” is reconciled with GAAP income from operations below:

 

     Three Months Ended  
     September 30,
2022
     September 30,
2021
 

GAAP income from operations

   $ 275,739      $ 261,913  

Amortization of acquired intangibles—cost of sales (A)

     6,374        11,059  

Amortization of acquired intangibles—operating expenses (A)

     7,950        7,707  

Acquisition-related expenses (A)

     745        —    
  

 

 

    

 

 

 

Non-GAAP income from operations

   $ 290,808      $ 280,679  
  

 

 

    

 

 

 


 

RMD First Quarter 2023 Earnings Press Release – October 27, 2022   Page of 10

 

RESMED INC. AND SUBSIDIARIES

 

Reconciliation of Non-GAAP Financial Measures

(Unaudited; $ in thousands, except for per share amounts)

The measures “non-GAAP net income” and “non-GAAP diluted earnings per share” are reconciled with GAAP net income and GAAP diluted earnings per share in the table below:

 

     Three Months Ended  
     September 30,
2022
     September 30,
2021
 

GAAP net income

   $ 210,478      $ 203,613  

Amortization of acquired intangibles—cost of sales, net of tax (A)

     4,835        8,435  

Amortization of acquired intangibles—operating expenses, net of tax (A)

     6,031        5,878  

Acquisition-related expenses (A)

     745        —    

Reserve for disputed tax position (A)

     —          4,111  
  

 

 

    

 

 

 

Non-GAAP net income (A)

   $ 222,089      $ 222,037  
  

 

 

    

 

 

 

GAAP diluted shares outstanding

     147,134        146,860  

GAAP diluted earnings per share

   $ 1.43      $ 1.39  

Non-GAAP diluted earnings per share (A)

   $ 1.51      $ 1.51  

 

(A)

ResMed adjusts for the impact of the amortization of acquired intangibles, acquisition-related expenses and the reserve for disputed tax positions from their evaluation of ongoing operations, and believes that investors benefit from adjusting these items to facilitate a more meaningful evaluation of current operating performance.

ResMed believes that non-GAAP diluted earnings per share is an additional measure of performance that investors can use to compare operating results between reporting periods. ResMed uses non-GAAP information internally in planning, forecasting, and evaluating the results of operations in the current period and in comparing it to past periods. ResMed believes this information provides investors better insight when evaluating ResMed’s performance from core operations and provides consistent financial reporting. The use of non-GAAP measures is intended to supplement, and not to replace, the presentation of net income and other GAAP measures. Like all non-GAAP measures, non-GAAP earnings are subject to inherent limitations because they do not include all the expenses that must be included under GAAP.

– More –


 

RMD First Quarter 2023 Earnings Press Release – October 27, 2022   Page 10 of 10

 

RESMED INC. AND SUBSIDIARIES

 

Revenue by Product and Region

(Unaudited; $ in millions, except for per share amounts)

 

     Three Months Ended  
     September 30,
2022 (A)
     September 30,
2021 (A)
     % Change     Constant
Currency (B)
 

U.S., Canada, and Latin America

          

Devices

   $ 339.5      $ 275.9        23  

Masks and other

     238.6        215.1        11    
  

 

 

    

 

 

    

 

 

   

Total Sleep and Respiratory Care

   $ 578.1      $ 491.0        18    

Software-as-a-Service

     105.9        97.5        9    
  

 

 

    

 

 

    

 

 

   

Total

   $ 684.0      $ 588.6        16    
  

 

 

    

 

 

    

 

 

   

Combined Europe, Asia, and other markets

          

Devices

   $ 178.0      $ 218.2        (18 )%      (10 )% 

Masks and other

     88.3        97.2        (9     3  
  

 

 

    

 

 

    

 

 

   

 

 

 

Total Sleep and Respiratory Care

   $ 266.3      $ 315.5        (16     (6

Global revenue

          

Devices

   $ 517.6      $ 494.2        5     9

Masks and other

     326.9        312.3        5       8  
  

 

 

    

 

 

    

 

 

   

 

 

 

Total Sleep and Respiratory Care

   $ 844.4      $ 806.5        5       9  

Software-as-a-Service

     105.9        97.5        9       9  
  

 

 

    

 

 

    

 

 

   

 

 

 

Total

   $ 950.3      $ 904.0        5       9  
  

 

 

    

 

 

    

 

 

   

 

 

 

 

(A)

Totals and subtotals may not add due to rounding.

(B)

In order to provide a framework for assessing how our underlying businesses performed excluding the effect of foreign currency fluctuations, we provide certain financial information on a “constant currency basis,” which is in addition to the actual financial information presented. In order to calculate our constant currency information, we translate the current period financial information using the foreign currency exchange rates that were in effect during the previous comparable period. However, constant currency measures should not be considered in isolation or as an alternative to U.S. dollar measures that reflect current period exchange rates, or to other financial measures calculated and presented in accordance with U.S. GAAP.

– End –